Catalent Pharma Solutions has formed exclusive development and licensing agreement with the privately held biopharmaceutical company, Cingulate Therapeutics to support the development of a series of new prescription pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) using Catalent's OptiDose drug-delivery platform.

The products, CTX-1301 and CTX-1302, are currently in pre-clinical development. Cingulate Therapeutics ‘s lead product, CTX-1301, is expected to complete initial Phase I/Phase II human trials in early 2015. Cingulate Therapeutics’ primary focus is to develop and commercialize the CTx products in the United States following FDA review and approval followed approval in the EU and other strategically important markets.

Catalent's OSDrC OptiDose is core tableting technology that enables the formulation and manufacturing of single or multi-cored tablets with differentiated controlled-release functionality and a range of unique dose forms, including fixed-dose combination tablets.

Source: Catalent Pharma Solutions